NovAliX and Max Planck join forces to advance Cryo-EM driven drug discovery

Collaboration will make vital process of translating scientific research and academic insights into real therapies more efficient and more effective

07-Mar-2024 - NovAliX, a specialized Contract Research Organization dedicated to enabling drug discovery, announces its long-term strategic partnership with the Max Planck Institute (MPI) for Multidisciplinary Sciences in Göttingen. Through this collaboration, NovAliX and the MPI aim to make the vital process ...

Cloud-based platform for analyzing cryo-EM data secures pre-seed investment

Dutch biotech start-up aims to accelerate the development of new active ingredients

04-Mar-2024 - CryoCloud, a biotech start-up based in Utrecht in the Netherlands, recently closed a financing round of 500,000 euros. The company has thus reached an important milestone on its way to optimizing cryo-electron microscopy (cryo-EM). CryoCloud was founded in 2021 by Munich-based Robert Englmeier, ...

New hope in the fight against RSV

Researchers discover promising drug candidate

13-Feb-2024 - The respiratory syncytial virus (RSV) causes severe lower respiratory tract infections, particularly in young children. To date, there is neither an antiviral therapy against the virus nor a vaccination for children. This is why researchers led by Thomas Pietschmann at TWINCORE, a joint ...

Device 'smells' seawater to discover, detect novel molecules

Promising for drug discovery in fragile ecosystems, including coral reefs

10-Nov-2023 - Under the ocean’s surface, marine organisms are constantly releasing invisible molecules. Some of the chemical clues reveal which creatures are nearby, while others could be used someday as medications. Now, researchers in ACS Central Science report a proof-of-concept device that “sniffs” ...

HeartBeat.bio raises € 4.5 million in Pre-Series A financing

New funds to drive development of organoid screening platform for cardiac drug discovery

03-Nov-2023 - HeartBeat.bio AG, a biotech company building a highly scalable human organoid and AI-supported drug discovery platform for heart disease, announced the closing of a € 4.5 million Pre-Series A round co-led by i&i Biotech Fund, Invest AG, aws Gründungsfonds II, and Tensor Ventures. The financing ...

SRI spins off AI-powered drug discovery platform Synfini, Inc.

Synfini to commercialize and scale automated compound testing for rapid drug production

09-Oct-2023 - SRI International announced it is spinning off Synfini, a biosciences platform that accelerates the process by which pharmaceutical and other companies can design, synthesize, and bring to market molecules for drug development. The technology brings together a suite of software and hardware ...

Abundant ‘secret doors’ on human proteins could reshape drug discovery

Identification of hidden vulnerabilities on surface of ‘undruggable’ proteins could transform treatment of disease

11-Apr-2022 - The number of potential therapeutic targets on the surfaces of human proteins is much greater than previously thought, according to the findings of a new study in the journal Nature. A ground-breaking new technique developed by researchers at the Centre for Genomic Regulation (CRG) in Barcelona ...

Study of hundreds of proteins in parallel

First highly scalable method developed to monitor protein levels and localizations in cells

20-Nov-2020 - CeMM researchers have developed a highly scalable method which allows for the study of hundreds of proteins in parallel in order to monitor the changes of their levels and localization in the cell. This novel strategy is a notable contribution, not only to drug development for future treatments ...

Midbrain organoids for automated chemical screening and disease research

Max Planck Innovation licenses process for the generation of organ-like tissue aggregates to biotech company StemoniX

05-Nov-2020 - Sometimes hundreds of thousands of potential therapeutics need to be tested in large-scale, fully automated experiments to identify a single effective drug. Most compounds do not work as desired, and some are even toxic. Since the development of the induced Pluripotent Stem (iPS) Cell technology ...

Bruker acquires Hamburg-based sensor start-up

27-Jun-2018 - Thanks to its innovative, patented sensor technologies, a portfolio company in the High-Tech Gründerfond (HTGF) has reached market maturity: USA’s Bruker Corporation has taken over Hamburg startup Sierra Sensors GmbH. Sierra Sensors develop and distribute biosensor-based analytical tools and ...